Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes
Piero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, Bernard Zinman, Stefan Hantel, Michaela Mattheus, Maximilian von Eynatten, Giuseppe Remuzzi, Audrey Koitka-Weber, Christoph Wanner, Piero Ruggenenti, Bettina J Kraus, Silvio E Inzucchi, Bernard Zinman, Stefan Hantel, Michaela Mattheus, Maximilian von Eynatten, Giuseppe Remuzzi, Audrey Koitka-Weber, Christoph Wanner
Abstract
Background: Diabetic kidney disease with nephrotic-range proteinuria (NRP) is commonly associated with rapid kidney function loss, increased cardiovascular risk, and premature mortality. We explored the effect of empagliflozin in patients with type 2 diabetes and cardiovascular disease, complicated by presence of this major risk factor for progressive kidney disease, in a post-hoc analysis of data from the EMPA-REG OUTCOME trial (NCT01131676).
Methods: Cox proportional hazards models were used to investigate the risk of cardiovascular and kidney outcomes in participants with and without NRP, defined by urine albumin-to-creatinine ratio (UACR) ≥2200 mg/g at baseline. Annual loss of eGFR during chronic treatment (eGFR slopes) and hypothetical time to projected end-stage kidney disease (ESKD), conditioning upon linearity of eGFR change over time if a patient did not decease before projected ESKD, were calculated using a random-intercept random-coefficient model. Safety was described based on investigator-reported adverse events.
Findings: 112 participants (pooled empagliflozin, n = 70; placebo, n = 42; median on-treatment follow-up of 1·9 years on placebo compared with 2·3 years on empagliflozin) presented with NRP at baseline; eGFR and UACR were balanced between treatments. Empagliflozin benefits on cardiovascular death, hospitalisation for heart failure, or kidney outcomes, were consistent in participants with and without NRP (pinteraction >0·1). Treatment effects of empagliflozin on adjusted annual mean eGFR slope were more pronounced in participants with NRP versus those without (pinteraction 0·005). Empagliflozin was estimated to double the median hypothetical time to projected ESKD in participants with NRP. The overall safety profile of empagliflozin was comparable between participants with and without NRP at baseline.
Interpretation: Our data suggests that empagliflozin might slow kidney function loss and delay the estimated onset of projected ESKD in patients with type 2 diabetes and cardiovascular disease complicated by NRP.
Keywords: Empagliflozin; Kidney disease; Nephrotic; Proteinuria; SGLT2 inhibitor; Type 2 diabetes.
Conflict of interest statement
PR and GR have no conflicts to report. BJK is an employee of Boehringer Ingelheim, the University Hospital of Würzburg and has received grants from the IZKF (Interdisziplinaeres Zentrum fuer klinische Forschung) of the University of Wuerzburg, and from Boehringer Ingelheim. SI reports consulting fees and honoraria from Intarcia Therapeutics, Daiichi-Sankyo, Lexicon Pharmaceuticals, Janssen, Sanofi, AstraZeneca, Boehringer Ingelheim, and Novo Nordisk. BZ has received grant support from Boehringer Ingelheim, AstraZeneca, and Novo Nordisk; and consulting fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen, Merck, Novo Nordisk, and Sanofi Aventis. SH, MM, MvE, and AKW are employees of Boehringer Ingelheim. CW reports honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Mitsubishi, and MSD.
© 2021 Published by Elsevier Ltd.
Figures
References
- Stoycheff N., Stevens L.A., Schmid C.H., et al. Nephrotic syndrome in diabetic kidney disease: an evaluation and update of the definition. Am J Kidney Dis. 2009;54(5):840–849.
- Vassalotti J.A., Stevens L.A., Levey A.S. Testing for chronic kidney disease: a position statement from the National Kidney Foundation. Am J Kidney Dis. 2007;50(2):169–180.
- Rossing K., Christensen P.K., Hovind P., Parving H.H. Remission of nephrotic-range albuminuria reduces risk of end-stage renal disease and improves survival in type 2 diabetic patients. Diabetologia. 2005;48(11):2241–2247.
- Lee Y.H., Kim K.P., Kim Y.G., et al. Clinicopathological features of diabetic and nondiabetic renal diseases in type 2 diabetic patients with nephrotic-range proteinuria. Medicine. 2017;96(36):e8047. Baltimore.
- Gerstein H.C., Mann J.F., Yi Q., et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286(4):421–426.
- Hallan S., Astor B., Romundstad S., Aasarod K., Kvenild K., Coresh J. Association of kidney function and albuminuria with cardiovascular mortality in older vs younger individuals: the HUNT II Study. Arch Intern Med. 2007;167(22):2490–2496.
- Jennings D.L., Kalus J.S., Coleman C.I., Manierski C., Yee J. Combination therapy with an ACE inhibitor and an angiotensin receptor blocker for diabetic nephropathy: a meta-analysis. Diabetes Med. 2007;24(5):486–493.
- Qin X., Dong H., Fang K., Lu F. The effect of statins on renal outcomes in patients with diabetic kidney disease: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2017;33(6)
- Cherney D., Lund S.S., Perkins B.A., et al. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes. Diabetologia. 2016;59(9):1860–1870.
- Cherney D.Z., Perkins B.A., Soleymanlou N., et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–597.
- Heerspink H.J.L., Stefansson B.V., Correa-Rotter R., et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446.
- Perkovic V., Jardine M.J., Neal B., et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
- Tanaka A., Nakamura T., Sato E., Node K. Therapeutic potential of tofogliflozin on nephrotic syndrome secondary to diabetic nephropathy. J Cardiol Cases. 2017;16(1):30–33.
- Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
- Wanner C., Inzucchi S.E., Lachin J.M., et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334.
- Butler J., Zannad F., Fitchett D., et al. Empagliflozin improves kidney outcomes in patients with or without heart failure. Circ Heart Fail. 2019;12(6)
- Neal B., Perkovic V., Mahaffey K.W., et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
- Wiviott S.D., Raz I., Bonaca M.P., et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
- Zinman B., Inzucchi S.E., Lachin J.M., et al. Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME) Cardiovasc Diabetol. 2014;13:102.
- Cherney D.Z.I., Zinman B., Inzucchi S.E., et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017;5(8):610–621.
- Wanner C., Heerspink H.J.L., Zinman B., et al. Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J Am Soc Nephrol. 2018;29(11):2755–2769.
- Lewis E.J., Hunsicker L.G., Clarke W.R., et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851–860.
- KDIGO CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:1–150.
- Skrtic M., Yang G.K., Perkins B.A., et al. Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration. Diabetologia. 2014;57(12):2599–2602.
- Castoldi G., Carletti R., Ippolito S., et al. Renal anti-fibrotic effect of sodium glucose cotransporter 2 inhibition in angiotensin II-dependent hypertension. Am J Nephrol. 2020;51(2):119–129.
- Kim S., Jo C.H., Kim G.H. Effects of empagliflozin on nondiabetic salt-sensitive hypertension in uninephrectomized rats. Hypertens Res. 2019;42(12):1905–1915.
- Ruggenenti P., Perna A., Gherardi G., et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet. 1999;354(9176):359–364.
- The GISEN Group Gruppo Italiano di Studi Epidemiologici in Nefrologia. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet. 1997;349(9069):1857–1863.
- Altemtam N., Russell J., El Nahas M. A study of the natural history of diabetic kidney disease (DKD) Nephrol Dial Transplant. 2012;27(5):1847–1854.
- Hladunewich M.A., Troyanov S., Calafati J., Cattran D.C. Metropolitan Toronto glomerulonephritis Registry. The natural history of the non-nephrotic membranous nephropathy patient. Clin J Am Soc Nephrol. 2009;4(9):1417–1422.
- Wanner C., Nangaku M., Kraus B.J., et al. Proceedings of the European Renal Association - 58th Congress with the European Dialysis and Transplant Association. 2021. Mediators of the improvement in kidney outcomes with empagliflozin in the EMPA-REG OUTCOME trial. Presented at the.
- Ruggenenti P., Cravedi P., Remuzzi G. Mechanisms and treatment of CKD. J Am Soc Nephrol. 2012;23(12):1917–1928.
Source: PubMed